Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Adi DiabHelen J GogasShahneen SandhuGeorgina V LongPaolo Antonio AsciertoJames M G LarkinMario SznolFabio FrankeTudor E CiuleanuCaio PereiraEva Muñoz CouseloFernanda Bronzon DamianMichael SchenkerAldo PerfettiCeleste LebbèGaëlle QuéreuxFriedegund MeierBrendan D CurtiCarlos RojasYull ArriagaHaisu YangMing ZhouShruthi RavimohanPaul StatkevichMary A TagliaferriNikhil I KhushalaniPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The PIVOT IO 001 study did not meet its primary end points of ORR, PFS, and OS. Increased toxicity was observed with BEMPEG plus NIVO versus NIVO.